Zim Innovation &

An independent R&D centre recognised by the DSIR, Govt. of India, has been the originator of differentiated generics based on innovative process technologies. Our manufacturing facilities are EU-GMP, WHO-GMP , ISO 9001 and NSF/ANSI 455-2 certified


Therapy Agnostic Products: Multiple Technology Platforms

Our technology aims at making available differentiated, novel dosage forms to our business associates for premium product leadership and health solutions to our patients providing unique & enhanced benefits affordably.

Multiparticulates offer better control on the release profiles of drug molecules and therefore are preferred for the designing of modified release dosage forms.

We have expertise to develop and manufacture pellets in various release profiles including immediate, delayed, controlled, sustained and targeted release.

Pellets with such modified release profiles improve patient convenience by reducing dosage frequency and have the least side effects.

Oral administration of bitter or unpleasant tasting drug is often the biggest barrier for developing medicines for special need patient populations like pediatric, geriatric and mentally challenged patients.

We have mastered the art of masking the taste of bitter molecules without affecting their dissolution profile and bio-availability, while maintaining adequate shelf life.

Our taste masked dry powders, dry syrups and orally disintegrating films have achieved extensive patient acceptability and hence have resulted in enhance patient compliance.

Directly compressible granules are just one step away from getting converted into end product i.e. tablets. We have  state-of-the-art technology to manufacture directly compressible granules, especially with modified release profiles. These granules can be directly compressed into tablets with minimal challenges at any manufacturing facility.

We empower our PFI customers with high technology products to address the unmet medical needs of their markets and work for the larger benefit of the patient community.

We are one of the few companies globally having in-house technology for the manufacturing of oral thin films

Our patented Thinoral® technology yield instantly wettable, rapidly dissolving, non-sticky, non-tacky and non-curving films with drug load as high as 50-60 mg of the active drug.

Our Mucostrip® technology is suitable for the delivery of drugs through sublingual and buccal routes.


3 State-of-the-art manufacturing units in Nagpur

Zim Labs has internationally accredited infrastructure with seamless technology integration for cutting edge manufacturing.

general facility

Solid Oral Dosage

Manufacturing Capabilities
DC Granules, Tablets, Pellets, Capsules & Dry Syrup


It has been constructed with adequate separation to cater to the activities required to manufacture different formulations, warehousing, and quality control.


Oral Thin Film Facility

Manufacturing Capabilities

EU-GMP, NSF/ANSI 455-2 ,WHO-GMP & ISO 9001

The state-of-the-art OTF manufacturing facility is capable of manufacturing 324 million strips per annum. This is a dedicated facility for the manufacturing of OTF in various treatment areas and has separate nutraceutical and pharmaceutical manufacturing areas.


Solid Oral Dosage

Manufacturing Capabilities
Tablets, Capsules, DC Granules

WHO-GMP & ISO 9001

The Cephalosporin facility manufactures Taste-Masked Preformulation and Formulation products which are supplied to international customers.

The two storeyed facility has a separate warehousing and quality-control area. The manufacturing operations are on the second floor with warehousing and QC on the ground floor.